

A photograph of a senior male golfer with a grey beard, wearing a white polo shirt, a dark baseball cap, and white golf gloves. He is standing on a golf course, looking down at a golf bag filled with clubs. The background shows a green golf course with trees and a body of water under a bright sky. A semi-transparent blue box is overlaid on the left side of the image, containing the company name and report title.

PROSTALUND AB

Interim report January-March 2025

First quarter

Januari 1 - March 31

- Net sales reached SEK 3,7 million (3,5)
- Operating result amounted to -5,0 MSEK (-4,7)
- Profit after tax amounted to -5,0 MSEK (-4,8)
- Earnings per share before and after dilution amounted to -1,39 SEK (-2,49)
- Cash flow from operating activities amounted to SEK -4,1 MSEK (-6,6)

Significant events during the period

- Older men treated with CoreTherm® for benign prostate enlargement have a lower risk of a prostate cancer diagnosis later in life compared to men treated with TURP according to a new Swedish registry study.
- New study confirms the favourable effect of CoreTherm® in patients with large prostates.
- Use of Schelin Catheter® before water vapour therapy is cost-effective.


Significant events after the end of the period

- ProstaLund AB (publ) initiates strategic review due to weakened liquidity and raises loans of SEK 2.5 million.
- First treatments with CoreTherm® Eagle will be performed next week - important milestone for ProstaLund.
- Per Langö leaves the board.
- ProstaLund's CEO resigns at his own request.
- First patients treated with CoreTherm® Eagle.
- ProstaLund AB (publ) comments on trading halt and plans to decide on a directed share issue.
- ProstaLund AB (publ) has decided to carry out a directed share issue of SEK 5.5 million to several existing shareholders, subject to the subsequent approval of the Annual General Meeting.
- On May 26, ProstaLund AB appoints Malin Melander as acting CEO.
- ProstaLund AB (publ) appoints Annette Colin as interim CFO and appoints former CEO Anders Kristensson as consultant in strategic and operational matters

Key figures


(SEK MILLION)	JAN-MAR 2025	JAN-MAR 2024	JAN-DEC 2024
Net sales	3,7	3,5	13,7
Gross Margin, (%)	74,0	69,7	69,5
Operating profit/loss, EBIT	-5,0	-4,7	-22,5
Cash flow from operating activities	-4,2	-6,6	-22,6
Cash and cash equivalents	2,4	6,9	7,8
Average number of employees	9	6	8

Sales distributed by category (SEKt)




Overview of the company's development

Number of CoreTherm® treatments sold in the Nordic region 2021-2025



Sales development per quarter 2021-2025 (SEKt)



Quarterly financial performance

All amounts in SEK thousand	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Net sales	3 748	3 948	3 461	2 816	3 500
Gross profit/loss	2 775	2 167	2 177	2 087	2 440
Gross margin (%)	74%	55%	63%	74%	70%
Overhead costs	-7 719	-8 685	-6 591	-9 242	-7 180
Operating profit/loss	-5 019	-6 153	-4 443	-7 162	-4 732
Profit/loss for the period	-5 036	-6 174	-4 489	-7 209	-4 759
Cash flow	-5 428	-4 299	8 741	-3 564	-8 075

Commercial information

In terms of sales, the first quarter of the year was slightly higher compared with the same quarter last year and the gross margin improved compared with both the previous quarter and the year, which is positive and we are now continuing the work of strengthening sales efforts among our customers at the same time as we are now entering the launch of CoreTherm® Eagle.

We will begin the launch at our centres of excellence in both Sweden and Denmark and then also start up internationally. As previously mentioned, we have a great interest in our treatment and have several positive discussions with potential new customers internationally.

With the launch of CoreTherm® Eagle, we will increase the number of treatments and give more patients the opportunity to benefit from our treatment, which is gratifying and we look forward to working with our centres to help more men with prostate problems to a better everyday life and future.

In connection with the EAU in Madrid at the end of March, we had the opportunity to demonstrate our product portfolio and we had a well-attended stand and great interest from all over the world. Several new contacts were made with both urologists and distributors in the BPH field, and over the past months we have worked intensively to follow up on these contacts and initiated several new discussions for both our standalone products and CoreTherm® Eagle.

For our standalone products, and primarily Schelin Catheter®, we have during the past quarter reviewed distributor agreements with the reason that we must ensure that our partners both can and have the right conditions to now also work with CoreTherm® Eagle. This means that we have chosen to actively terminate a couple of agreements, which affected sales during the past quarter, but it gives us the right long-term conditions for our entire portfolio.

Our published studies on the treatment of large prostates have attracted great interest internationally and where we as a company have a clear advantage over our competitors, as we do not have the same limitation in size and can show good treatment results. The results of the Danish study show that more than 80% of the patients who suffered from urinary retention and needed either indwelling catheters or self-catheterisation were able to urinate spontaneously at the follow-up six months after treatment.

We are very pleased that the first patients have been successfully treated with our new CoreTherm® Eagle platform. This is an important milestone for us and a clear result of the focused work carried out internally. With CoreTherm® Eagle, the opportunity opens up to offer more clinics, both in the Nordic region and globally, an effective treatment method.

Financial information

Net sales and profit/loss

Net sales amounted to SEK 3,748 (3,500) thousand for the first quarter, which was an increase of 7.1 per cent compared to the corresponding quarter last year. Denmark has had a good development during the first quarter.

The gross margin strengthened during the quarter and totalled 74.0% (69.7).

The operating result for the first quarter amounted to SEK -5,019 (-4,732) THOUSAND.

Profit after tax totalled SEK -5,036 (-4,759) thousand.

Investment

Investments in tangible fixed assets totalled SEK 50 (0) thousand for the first quarter. Investments in intangible fixed assets totalled SEK 1,045 (1,364) thousand, which mainly relates to the upgrade of the company's new CoreTherm® Eagle platform.

Financial position and financing

Cash flow from operating activities for the first quarter totalled SEK -4,161 (-6,611) thousand.

Equity totalled KSEK 50,073 (50,530) and the equity ratio amounted to 89 (88) per cent.

Cash and cash equivalents at 31 March 2025 amounted to KSEK 2,394 (6,944).

Organisation

At the end of the period, the company had 9 (6) employees, of whom 6 (4) were women and 3 (2) men. The average number of employees during the period was 6 and the number of consultants was 8.

Research and development

Development work is carried out in-house in co-operation with external clinics and technical consultants. Development work is focused on new development and further refinement of the current product portfolio.

Insurance

ProstaLund has customary business insurance that also includes product liability cover. The insurance cover is subject to ongoing review. The Board considers that the business insurance is adapted to the current scope of the business.

Disputes

ProstaLund is not a party to any legal or arbitration proceedings. Nor is the Board of Directors aware of any circumstances that could lead to any such legal process being imminent.

Risk factors

ProstaLund's business is affected by a number of risks, the effects of which could have a negative impact on its future, results or financial position.

The latest annual report and prospectus, which are available on the company's website www.prostalund.se, contain a description of the risk factors. Listed below, in no particular order, are the risk factors considered to be of greatest significance:

- Dependence on funding
- Dependence on key personnel
- Regulatory approvals
- Product liability
- Currency risk
- Competition
- Disputes
- Changes in legislation

Prerequisites for continued operation

This financial information has been prepared on a going concern basis. The company has historically recognised losses. In preparing the communication, management has based its assumptions on existing cash and cash equivalents, increased sales and the potential availability of other financing.

In estimating future expenditures, management has recognised that certain expenditures are within management's control and may be eliminated or deferred. Management and the Board recognise that there are uncertainties in estimating future cash flows and uncertainties in financing operations.

If the Group is unable to continue as a going concern for any reason, it may affect the Company's ability to realise the carrying amounts of its assets, in particular related to capitalised development expenditure, and to pay its liabilities at the normal pace and in the amounts disclosed in its interim financial statements.

Transactions with related parties

Contracts with members of the Board of Directors

The Company has entered into consultancy agreements with some of its Directors. The consultancy agreements regulate the performance by the Board members of tasks that cannot be considered to constitute duties normally incumbent on a Board member. The other members of the Board of Directors and the CEO must approve such work before it is carried out.

Royalty agreement

The company has previously entered into a royalty agreement with Schelin Medicin AB regarding the rights to the products Coreflow® and Schelin Catheter®. The agreement means that two (2) per cent of the invoiced amount for these products will be paid in royalties to Schelin Medicin AB, provided that the company reports

a profit and that a patent is granted. The royalty may amount to a maximum of SEK 4 million per year and a maximum of SEK 20 million in total. The agreement shall terminate when an amount of SEK 20 million has been paid to Schelin Medicin AB.

Valuation of intangible assets

The capitalised development expenditure recognised is subject to impairment testing by management. The most critical assumption evaluated by management is whether the intangible asset is expected to generate future economic benefits that are at least equal to the carrying amount of the intangible asset. Management's judgement is that the expected future cash flows are sufficient to justify the carrying amount of the intangible asset and therefore no impairment loss has been recognised. However, the valuation is based on and dependent on the going concern assumption.

Remuneration policy

The guiding principle is that ProstaLund shall offer its management and key personnel competitive remuneration based on market conditions, company performance and individual performance. The design of the remuneration shall ensure that management and key employees and shareholders have common goals.

Shares

ProstaLund is listed on Nasdaq First North Growth Market. The company is traded under the ticker PLUN and the ISIN code SE0023468418. Certified Adviser is Västra Hamnen Corporate Finance AB.

The number of shares at the end of the period was 3,624,052 and the quota value was SEK 4.0 per share. All shares are of the same type and have the same voting rights.

In 2024, a new share issue was carried out at the same time as a consolidation of the number of shares was made at a ratio of 1:40.

Annual report

The Annual Report for 2024 will be published no later than three weeks before the Annual General Meeting. The Annual Report will be available on the company's website www.prostalund.se.

Annual General Meeting

The Annual General Meeting for 2024 is held on May 30 in Lund.

The date set for the 2025 AGM is June 25 in Lund.

Financial calendar

- 2025-08-21 Interim report Apr-Jun 2025
- 2025-11-07 Interim report Jul-Sep 2025
- 2026-02-25 Year-end report 2025

Scope of the report

This interim report covers the period from 1 January 2025 to 31 March 2025. The comparative information in the report refers to the corresponding period in 2024, unless otherwise stated. All information in the report refers only to the parent company ProstaLund AB (publ), i.e. no consolidation of wholly owned subsidiaries takes place as these only account for a small part of the business.

Accounting policies

This report has been prepared in accordance with the Annual Accounts Act and the general advice of the Swedish Accounting Standards Board. The accounting principles and calculation methods applied are consistent with the accounting principles used in the preparation of the latest annual report.

Audit

This report has not been reviewed by the company's auditors.

Assurance of the Board of Directors and Managing Director

The Board and the Managing Director assure that the interim report provides a fair overview of the company's operations, position and results, and describes significant risks and uncertainty factors that ProstaLund AB face.

Lund, May 30 2025

Tomas Eriksson
Board member

Paul de Potocki
Board member

Tom Rönnlund
Board member

Marianne Östlund
Board member

Malin Melander
Acting CEO

Sharholder information

For questions about this report, please contact:

Tom Rönnlund Board member, ProstaLund AB (publ)

- Phone: +46 727 320 321
- E-mail: tom.ronnlund@orntorpet.se

Publication

This information is information that ProstaLund AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on May 30, 2025.

ProstaLund is listed on Nasdaq First North Growth Market. The company is traded under short name PLUN and ISIN code SE0023468418.

Certified Advisor is Västra Hamnen Corporate Finance AB.

Income Statement in Summary

All amounts in SEK thousand	JAN-MAR 2025	JAN-MAR 2024	JAN-DEC 2024
Operating income			
Net sales	3 748	3 500	13 725
Cost of goods sold	-973	-1 060	-4 854
Gross profit	2 775	2 440	8 871
Sales & Marketing expenses	-3 760	-3 443	-15 528
Administrative expenses	-2 331	-2 666	-10 629
Research and development costs	-1 628	-1 071	-5 541
Other operating income	54	258	876
Other operating costs	-129	-250	-539
Operating profit/loss	-5 019	-4 732	-22 490
Profit/loss from financial items			
Interest income and similar profit/loss items	5	9	36
Interest expenses and similar profit/loss items	-22	-36	-177
Profit/loss after financial items	-5 036	-4 759	-22 631
Profit/loss for the period	-5 036	-4 759	-22 631

Per share data

SEK	JAN-MAR 2025	JAN-MAR 2024	JAN-DEC 2024
Earnings per share, SEK (basic and diluted)	-1,39	-2,49	-6,94
Equity per share, SEK	13,82	26,39	15,23
Equity-asset ratio, %	89%	88%	90%
Number of outstanding shares	3 624 052	1 914 718	3 624 052
Average number of outstanding shares	3 624 052	1 914 718	3 258 651
Share value at the end of the period, SEK	7,30	42,60	7,54

Note: All figures above concerns the parent company ProstaLund AB (publ). For more info look at page 6 under Scope of the report.

Definitions of financial ratios

Earnings per share

Profit/loss for the period divided by average weighted number of shares.

Equity-asset ratio

Equity divided by total assets.

Equity per share

Equity divided by number of shares at the end of the period.

Balance Sheet in Summary

All amounts in SEK thousand	2025-03-31	2024-03-31	2024-12-31
ASSETS			
Intangible assets	35 394	29 374	34 378
Property, plant & equipment	822	346	813
Financial assets	0	464	0
Inventories	13 657	15 957	14 345
Trade receivables	2 278	2 097	2 647
Other receivables	1 687	2 000	1 633
Cash and bank balances	2 394	6 944	7 822
Total assets	56 232	57 182	61 638
EQUITY AND LIABILITIES			
Equity	50 073	50 530	55 181
Interest-bearing liabilities, longterm	433	833	533
Current interest-bearing liabilities	400	400	400
Liabilities to group companies	0	0	122
Trade payables	3 655	3 859	3 373
Other liabilities	1 671	1 560	2 029
Total equity and liabilities	56 232	57 182	61 638

Summary statement of changes in equity

All amounts in SEK thousand	2025-03-31	2024-03-31	2024-12-31
Opening balance	55 181	55 289	55 289
Result from merger			-249
New share issues	-	-	26 952
Costs of new share issues	-72	-	-4 180
Profit/loss for the period	-5 036	-4 759	-22 631
Closing balance	50 073	50 530	55 181

Note: All figures above concerns the parent company ProstaLund AB (publ). For more info look at page 6 under Scope of the report.

Cash Flow Analysis in Summary

All amounts in SEK thousand	JAN-MAR 2025	JAN-MAR 2024	JAN-DEC 2024
Profit/loss after financial items	-5 036	-4 759	-22 631
Adjustments for non-cash items	70	78	962
Cash flow from operating activities before changes in working capital	-4 966	-4 681	-21 669
Changes in working capital	805	-1 930	-922
Cash flow from operating activities	-4 161	-6 611	-22 591
Capitalization of development expenditure	-1 045	-1 364	-6 452
Acquisition/disposal of property, plant & equipment	-50	-	-537
Cash flow from investing activities	-1 095	-1 364	-6 989
New share issue	-	-	26 952
Transaction costs attributable to new share issue	-72	-	-4 180
Change in bank overdraft facilities	-	-	4 030
Change in bank overdraft facilities	-100	-100	-4 430
Cash flow from financing activities	-172	-100	22 372
Total cash flow for the period	-5 428	-8 075	-7 208
Infusion of cash			11
Cash and cash equivalents at start of period	7 822	15 019	15 019
Cash and cash equivalents at end of period	2 394	6 944	7 822

Note: All figures above concerns the parent company ProstaLund AB (publ). For more info look at page 6 under Scope of the report.

Business overview

The Company in brief

ProstaLund AB is a Swedish company with headquarters in Lund. The company's organisation number is 556745-3245. ProstaLund is a Swedish public limited company registered with the Swedish Companies Registration Office on 4 December 2007. The Board of Directors has its registered office in the municipality of Lund and operations are based in Sweden. The company's office address is Scheelevägen 19 in Lund with telephone number 046-12 09 08. The company's website is www.prostalund.se. The company is a CSD company and its share register is maintained by Euroclear Sweden AB. In addition to ProstaLund, which is the parent company, the Group includes the wholly owned subsidiary CoreTherm Medical Inc ('CMI').

Introduction to the Company's operations

The Company develops, markets and sells urological products. The majority of sales are through recurring sales of disposable catheters, antennas and other accessories used together with the Company's platform in the treatment of BPH.

The Company has a treatment concept (CoreTherm® Concept) for personalised heat treatment for the condition benign prostatic hyperplasia, also known as BPH or BPE, which mainly affects men over the age of 50.

In recent years, the company has developed a new platform, CoreTherm® Eagle, which received market authorisation through a CE mark from outside the EU's Medical Device Regulation (MDR) in February 2023.

The platform now includes an inbuilt computer, real-time temperature reading, patient data storage and inbuilt recommendations for treating physicians. The company believes that CoreTherm® Concept is one of the best treatments for BPH on the market in terms of parameters such as treatment outcome, ability to treat regard-

less of prostate size, re-treatment frequency, treatment time, fewer complications compared to surgery, learning time for treating physicians and cost of treatment. CoreTherm® Concept consists of several patented and unique inventions where the machine's treatment control is based on 25 years of research and clinical experience.

In addition, the Company has two stand-alone products, Schelin Catheter® and CoreFlow® Soft Stent. It is the Company's view that the products are unique as there are no similar products on the market due to the fact that the Company holds patents for both products in the markets in which the Company operates.

The Company's product offering is the CoreTherm® Concept, which consists of an anaesthetic catheter (Schelin Catheter®), treatment catheter (CoreTherm® Catheter) and aftercare catheter (CoreFlow® Soft Stent).

The Schelin Catheter® and CoreFlow® Soft Stent are also sold for use in other treatment modalities outside the CoreTherm® Concept.



CoreTherm® Eagle



CoreTherm® Catheter

CoreTherm® Concept – Treatment concept

CoreTherm® Concept is a patented and personalised treatment concept for BPH/BPE using heat. CoreTherm® Concept is currently used mainly in public hospitals and private clinics in the Nordic countries. The treatment is evidence-based and has the same end result as surgery¹.

The concept has a number of advantages:

- The size of the prostate does not limit the method
- The treatment is done under local anaesthesia, compared to general anaesthesia in surgery
- Maximum treatment time is 15 minutes

During a CoreTherm® Concept treatment, the temperature is measured in real time. The treatment effect can thus be calculated continuously and the temperature monitoring allows the doctor or nurse in charge to control the treatment. The treatment takes a maximum of 15 minutes and the entire visit to the clinic takes about 1 hour.

Schelin Catheter® - Injection tool

The Schelin Catheter® is a patented and unique product that has a needle built into the catheter for intraprostatic and periprostatic injection of drugs directly into the prostate. The Schelin Catheter® administers anaesthetics and adrenaline to manage pain and prostatic blood flow during a CoreTherm® Concept treatment of BPH, and the catheter thus plays a central role in the development of the treatment concept.

The product can also be used in other contexts, such as for local anaesthesia and other treatment procedures for prostate disorders, where drugs need to be administered into the prostate sterile.

1. Mattiasson A., Wagrell L., Schelin S., et al: Five-year follow up of feed-back microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 69, 91-97, 2007

CoreFlow® Soft Stent – Aftercare product

CoreFlow® Soft Stent is a patented and unique product. The product is a hybrid between a catheter and a stent. The product has many applications:

- The product can be used as a disposable product after BPH treatment regardless of the treatment method.
- The product can also be used as a diagnostic tool and simulate the treatment outcome of an invasive anti-obstruction procedure, microwave therapy (TUMT) or transurethral resection (TURP).
- The product is also an alternative to indwelling catheters (KAD) in case of urinary retention, enabling self-drainage and reducing the risk of urinary tract infection.

CoreFlow® Soft Stent can partially replace urodynamic tests, and can be used where these tests are not applicable.

This product is also used outside the CoreTherm® Concept treatment and is sold as a stand-alone product internationally together with the Schelin Catheter®.



Schelin Catheter®



CoreFlow® Soft Stent



ProstaLund is a Swedish medtech company, a leader in the development of innovative urology products and treatments. ProstaLund has patented CoreTherm®, customised thermal treatment of Benign Prostatic Enlargement (BPE)

ProstaLund AB
Scheelevägen 19
SE-223 63 Lund

info@prostalund.com
Phone: +46 46-12 09 08
www.prostalund.se

